ENTO Stock Price Chart
5D
1M
3M
6M
YTD
1Y
5Y
ENTO Fundamental Analysis
buy
Moderate Buy
Buy
Hold
Sell
High
Averages
Low
Analyst
Rating
Action
Price Target
Date
Rating Reason
ENTO News
5.0
02-14NewsfilterEntero Therapeutics Appoints Richard Paolone as CEO
8.5
02-07NewsfilterEntero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
8.5
02-07Business InsiderEntero Therapeutics secures $2M revolving loan, appoints three new directors
7.0
2024-12-06PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders
7.0
2024-12-06Globenewswire$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF
ENTO FAQs
What is surpport and resistant level for ENTO Stock?
The S1 support level for ENTO Stock is $0.45 ,The R1 resistant level for ENTO Stock is $0.61.
What is the current price of ENTO Stock?
What is the market cap of Entero Therapeutics Inc?
What is Entero Therapeutics Inc (ENTO)'s business?
How many employees does ENTO have?
ENTO Key Stats
High
0.562607
Vol
105.11K
Low
0.480
Amount
52.12K
Open
0.4835
VWAP
0.50
Mkt Cap
2.53M
ENTO Company Profile
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
